Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Videum

- PMLiVE

Changing the narrative: why hidden struggles matter

On Suicide Prevention Day, we’re focusing on something often overlooked: the difference between what’s visible and what’s actually being carried. Many people living with long-term or chronic illness experience challenges...

Mednet

- PMLiVE

Cutting the friction from health comms through whole-person design

Good design can’t change the reality of illness, remove the pain, or stop the uncertainty. But it can stop learning what comes next from being another burden to carry.

Mednet

- PMLiVE

The value: why localisation pays off across global trials

Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.

Cuttsy + Cuttsy

- PMLiVE

The solution: Good localisation doesn’t feel translated

Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every market.

Cuttsy + Cuttsy

- PMLiVE

Where translation falls short in practice

Discover why translation alone is not enough in global clinical trials and how expert localisation improves participant understanding, trust and engagement.

Cuttsy + Cuttsy

- PMLiVE

The silent drop-off: How disengagement shows up in everyday behaviour

In healthcare, disengagement rarely announces itself. It doesn’t always appear as refusal or a clear decision to stop treatment. More often, it shows up quietly, in what is delayed, avoided...

Mednet

- PMLiVE

Minds + Assembly Launches Assembled Intelligence and Adds Stratevi to Expand Market Access and HEOR Solutions

New York, NY — 10.23.2025 — Minds + Assembly, a leading healthcare marketing firm, today announced the launch of Assembled Intelligence, an integrated communications and commercialization platform designed to unite...

BOLDSCIENCE

- PMLiVE

Uniphar On Track to Achieve SBTi Target of Halving Scope 1 and 2 Emissions by 2030

[Dublin, 9th October 2025] Uniphar, a global leader in pharmaceutical and medtech solutions, is making progress towards its near-term Science Based Targets initiative (SBTi) goal of halving Scope 1 and...

Uniphar

Streamlining European expansion for cell and gene therapies

Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe...

Uniphar

- PMLiVE

Current CGT landscape and future outlook  

What makes CGT unique  Cell and gene therapy (CGT) is a unique treatment that uses cells and genetic material to treat and cure diseases. Personalized to the patient, CGT’s offer...

Uniphar

- PMLiVE

Building for Success: Aligning Preclinical and Phase 1 Strategy with Commercial Goals 

This article concludes our three-part series on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. The first article explored the unique scientific and logistical challenges of...

Uniphar

- PMLiVE

Navigating the complexities of launch preparation for Cell and Gene Therapy

Cell and gene therapies (CGT) provide transformative treatment that can treat conditions that were previously considered untreatable. As described in the previous article in this series, most CGTs target patients...

Uniphar

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links